Chronic osteomyelitis
Chronic OM · Infectious Disease
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Chronic osteomyelitis features necrotic bone (sequestrum), biofilm and often sinus tracts, frequently following trauma, surgery or contiguous spread. Cure usually needs surgical debridement combined with prolonged targeted antibiotics.
Red flags
- Systemic sepsis or expanding abscess
- Exposed hardware with instability
- Neurovascular compromise of the limb
- Malignant transformation of a chronic sinus (Marjolin ulcer)
- Failure to improve despite therapy (inadequate debridement)
Assessment
Differential diagnosis
- Acute osteomyelitis
- Soft-tissue infection/abscess only
- Bone tumour or metastasis
- Charcot neuroarthropathy
- Non-infective sinus/fistula
Investigations
- MRI to define bone and soft-tissue involvement
- Deep bone biopsy for culture and histology (hold antibiotics if stable)
- Inflammatory markers (CRP, ESR) for monitoring
- Plain radiographs (sequestra, involucrum)
- Blood cultures if systemically unwell
- Assess vascular supply and diabetic status
Management
- Confirm diagnosis with imaging and deep bone biopsy cultures
- Withhold antibiotics before sampling if clinically stable to improve yield
- Optimise host factors (glycaemic control, nutrition, smoking cessation, vascular supply)
- Plan surgical debridement with removal of sequestra and dead space management
- Obtain intraoperative cultures to guide therapy
- Start targeted antibiotics after sampling, including biofilm-active agents where appropriate
- Give a prolonged course, transitioning to oral where bioavailable options exist
- Manage dead space (antibiotic beads/spacers, flaps) and skeletal stability
- Monitor clinical, biochemical and imaging response
- Treat associated soft-tissue defects with plastic surgery input
- Plan staged reconstruction if needed
- Arrange long-term follow-up for relapse
Drugs & doses
Flucloxacillin 2 g IV every 6 h (MSSA), consider adding rifampicin 450 mg PO twice daily for biofilm
Vancomycin IV (AUC-guided) for MRSA, plus rifampicin where appropriate
Oral switch: ciprofloxacin 750 mg PO twice daily plus rifampicin 450 mg PO twice daily (susceptible organisms)
Co-amoxiclav 625 mg PO three times daily (culture-directed alternative)
Typical total duration 6 weeks (often with early oral switch supported by OVIVA evidence)
Disposition
Combined orthopaedic/ID (bone infection MDT); admit for surgery; OPAT for prolonged therapy.
Complications & pitfalls
- Recurrence/relapse (biofilm persistence)
- Pathological fracture and non-union
- Amputation
- Secondary amyloidosis (long-standing)
- Squamous carcinoma in chronic sinus
Exam pearls
- Surgery is central; antibiotics alone fail against sequestra and biofilm
- The OVIVA trial supports early oral switch when suitable agents exist
- Rifampicin adds biofilm activity but never use as monotherapy (resistance)
- Deep bone culture beats sinus-tract swabs for pathogen identification
- Address dead space and host optimisation to prevent relapse
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.